Agilis teams up with Intrexon to pursue Friedreich's ataxia
This article was originally published in Scrip
Executive Summary
Agilis Biotherapeutics has entered into a deal with synthetic biology firm Intrexon to develop DNA-based therapeutics for the rare genetic disease, Friedreich's ataxia.